LIVER RFA COMPLICATIONS
RECOGNITION, MANAGEMENT, AND WHEN TO SEEK HELP
Liver RFA is a safe procedure at experienced centres — major complications occur in approximately 2–4% of cases. Knowing what complications look like and how they are managed gives patients the knowledge to respond appropriately when symptoms develop.
analyticsAt a Glance
- check_circleMajor complication rate 2–4%; 30-day mortality <1% at experienced centres
- check_circleMost serious complications have specific recognisable symptom patterns
- check_circleHaemorrhage and bile duct injury are the two complications requiring most vigilance
- check_circleMost complications are manageable with timely recognition and appropriate interventional or medical care
Liver RFA Complication Rates
Published complication rates from major liver RFA series and systematic reviews — providing context for the overall safety profile.
Liver RFA Complication Incidence — Published Series
Rates from published series of CT-guided percutaneous liver RFA. Minor complications (self-limiting, no intervention needed) excluded from major complication count.
- Overall Major Complication Rate2–4%
- Intraperitoneal Haemorrhage1–2%
- Bile Duct Injury / Biloma1–2%
- Abscess / Infection0.5–1.5%
- Thermal Injury (adjacent structures)0.5–1%
- Needle Track Seeding<1%
- 30-Day Mortality<1%
Intraperitoneal Haemorrhage: The Most Urgent Complication
Bleeding from the liver surface or intrahepatic vessels is the most acutely dangerous liver RFA complication. It requires immediate recognition and management.
“Significant post-RFA haemorrhage typically presents within the first 4–6 hours after the procedure. The immediate post-procedure observation period is specifically designed to catch this. Delayed haemorrhage (days 1–3) is less common but occurs and requires patient vigilance at home.”
How Haemorrhage Presents
Acute haemorrhage: sudden severe right upper quadrant pain; falling blood pressure; rapid heart rate; pallor; sweating. May occur during the procedure (identified on immediate post-ablation CT) or in the hours after. Delayed haemorrhage (days 1–3): progressive abdominal discomfort, shoulder tip pain from diaphragmatic irritation, fatigue beyond expected PAS, distension.
Management of Haemorrhage
Minor haemorrhage (subcapsular haematoma, small volume bleeding contained within the liver capsule): observation, IV fluids, serial monitoring. Resolves spontaneously in most cases. Significant active bleeding: CT angiography confirms bleeding vessel; transarterial embolisation (TAE) of the bleeding vessel is the primary intervention. Emergency surgery for rare cases of uncontrolled haemorrhage not amenable to TAE.
Bile Duct Injury: Biloma and Biliary Stricture
Thermal injury to bile ducts adjacent to the ablation zone causes two distinct complications — biloma (bile collection) and biliary stricture. Both are more common for central hilar tumours near the biliary confluence.
Biloma: Bile Leak with Collection
Thermal injury to a bile duct causes a leak — bile accumulates as a fluid collection (biloma) adjacent to the ablation zone. Presents in the first 1–3 weeks: fever that doesn't resolve on expected timeline; mild jaundice; right upper quadrant pain. Diagnosed by CT (fluid collection) and MRCP or HIDA scan (confirms bile leak). Management: endoscopic biliary stenting (ERCP) to decompress the bile duct; percutaneous drainage of the biloma if large.
Biliary Stricture: Late Complication
Thermal injury to a bile duct can cause progressive fibrosis and ductal narrowing — presenting weeks to months after ablation as rising bilirubin, jaundice, and itching. Most common for peribillary tumours where ablation margin necessarily includes ductal tissue. Management: endoscopic balloon dilation and biliary stenting; severe cases may require hepaticojejunostomy (surgical biliary bypass). Biliary stricture risk is the primary reason experienced operators carefully plan peribillary tumour ablation with aggressive hydrodissection or chilled biliary perfusion.
Liver RFA Complication Summary Table
A comprehensive overview of all recognised liver RFA complications with presentation, rate, and management.
| Complication | Rate | Key Symptoms | Management | When to Seek Help |
|---|---|---|---|---|
| Intraperitoneal haemorrhage | 1–2% | Severe RUQ pain; hypotension; pallor | Observation (minor) or TAE (significant) | Immediately — emergency care |
| Biloma (bile leak) | 1–2% | Persistent fever; RUQ pain; jaundice (weeks 1–3) | ERCP stenting; percutaneous drainage | Within 24 hours of symptom onset |
| Biliary stricture | 0.5–1% | Jaundice; itching; rising bilirubin (weeks to months) | Endoscopic dilation and stenting | Non-urgent but prompt — days |
| Hepatic abscess | 0.5–1.5% | Fever >38.5°C with rigors; RUQ tenderness (days 5–14) | IV antibiotics; CT-guided drainage | Urgently — within hours of rigors |
| Pleural effusion | 1–3% | Breathlessness; pleuritic chest pain (days 3–10) | Observation (minor) or thoracocentesis | If significant breathlessness |
| Thermal bowel injury | <1% | Severe abdominal pain; peritonism; fever (days 1–3) | Surgical consultation — may need resection | Emergency — immediately |
| Needle track seeding | <1% | Subcutaneous nodule along needle track (weeks to months) | Surgical excision or re-ablation | Non-urgent — at routine follow-up visit |
| Post-ablation syndrome | 50–80% | Fever 37.5–38.5°C; fatigue; flu-like (days 1–10) | Paracetamol and rest — self-limiting | If fever >38.5°C or >10 days |
Needle Track Tumour Seeding: A Rare but Important Risk
Needle track seeding — implantation of tumour cells along the electrode insertion path — is a recognised but uncommon complication of liver RFA that was more concerning in early series and has been substantially reduced by technique.
Incidence and Presentation
Needle track seeding occurs in <1% of liver RFA procedures in most modern series. It presents as a subcutaneous nodule palpable under the skin along the electrode entry path — typically appearing weeks to months after ablation. Historically higher rates (1–2%) were reported when electrode withdrawal was not combined with track ablation; modern techniques have reduced this substantially.
Prevention and Management
Prevention: track ablation during electrode withdrawal (many modern systems incorporate this automatically); minimising the number of electrode passes; using probe-containing needle sheaths. Management: needle track seeding deposits are typically small and superficial — surgical excision or local ablation of the seeding deposit is effective in most cases. Detection: inspect the needle entry site at each follow-up visit and report any subcutaneous nodule to the treating team.
Related RFA Patient Safety Topics
Related RFA safety and recovery resources.
Frequently Asked Questions
Common questions about liver RFA complications.
About Complications
My liver function tests are high after my RFA. Is that dangerous?
A transient rise in liver enzymes (AST, ALT) is expected after liver RFA — the ablated hepatocytes release their contents into the bloodstream as they die. Elevations of 3–5× normal in the first week are common and expected, declining progressively to near-normal by 4–6 weeks. Concern arises if: LFTs continue rising rather than falling after day 7, bilirubin rises substantially (may indicate bile duct injury), or the enzyme elevation is accompanied by clinical deterioration. Routine LFTs at the 4–6 week follow-up confirm recovery to baseline.
How do I know if I have a liver abscess after RFA?
Hepatic abscess after liver RFA typically presents 1–3 weeks after the procedure with: fever above 38.5°C with or without rigors (shaking chills); persistent or new right upper quadrant pain and tenderness; general deterioration in how you feel. This is distinctly different from normal post-ablation syndrome which typically improves by day 10. If you have significant fever with rigors at any point, or persisting fever beyond 10 days, seek urgent medical review — CT of the liver will identify any abscess requiring drainage.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Concerned About Symptoms After Liver RFA?
If you are experiencing symptoms after liver RFA and are unsure whether they are normal, contact your treating team. For urgent symptoms (severe pain, high fever with rigors, jaundice), seek emergency care immediately.
For informational purposes only. New or worsening symptoms after liver RFA require prompt medical evaluation. This guide does not replace clinical assessment.